Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt.
This review takes a sceptical view of the impact of breast cancer studies that have used microarrays to identify predictors of clinical outcome. In addition to discussing general pitfalls of microarray experiments, we also critically review the key breast cancer studies to highlight methodological problems in cohort selection, statistical analysis, validation of results and reporting of raw data. We conclude that the optimum use of microarrays in clinical studies requires further optimisation and standardisation of methodology and reporting, together with improvements in clinical study design.
Ahmed
Ahmed Ashour
AA
Cancer Genomics Programme, Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, UK.
Brenton
James D
JD
D001943:Breast Neoplasms / Q000235:genetics* / Q000628:therapy*; D002986:Clinical Trials as Topic; D023381:Endpoint Determination; D005260:Female; D020869:Gene Expression Profiling; D005819:Genetic Markers; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D011379:Prognosis; D012107:Research Design; D016896:Treatment Outcome
D005819:Genetic Markers